MYQORZO: EC Approval, Differentiated Label, and Global HCM Expansion Support Buy on CYTK

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics and keeping the price target at $136.00.

Joseph Pantginis has given his Buy rating due to a combination of factors tied to MYQORZO’s expanding global footprint and differentiated profile in obstructive hypertrophic cardiomyopathy. He highlights that the EC authorization, following prior clearances in the U.S. and China, secures access in all major markets and should support meaningful worldwide commercial adoption beginning with a German launch in 2Q26 and broader European roll‑out thereafter.

Pantginis also points to specific label elements in Europe that may enhance the drug’s real‑world competitiveness, including greater dosing flexibility that can reduce monitoring burden and a simpler initiation pathway versus Camzyos. He notes that safety, monitoring, and drug‑interaction language remains manageable and broadly aligned with the U.S. label, while ongoing and planned sNDA and Phase 3 programs in additional HCM settings offer further upside to the long‑term revenue opportunity, reinforcing his positive stance on CYTK shares.